Loading…
Premium Health Management Inc. was cited for misbranding compounded semaglutide and tirzepatide products sold through their website in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs when it was not, and made misleading claims suggesting the products were FDA-approved or evaluated for safety and effectiveness, despite compounded drugs not receiving FDA approval. The violations included false or misleading labeling and advertising under sections 502(a) and 502(bb) of the FDCA, resulting in misbranded products being introduced into interstate commerce.